Z3 Capital Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Z3 Capital Partners’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.43M	Buy	76,530 +4,500	+6%	+$91K	0.3%	65
2026 Q2	$1.44M	Buy	72,030 +4,681	+7%	+$82.7K	0.3%	62
2026 Q1	$1.1M	Buy	67,349 +500	+0.7%	+$8.36K	0.28%	71
2025 Q4	$1.12M	Buy	+66,849	New	+$1.12M	0.27%	68

Other funds holding HQL

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Flagship Harbor Advisors Boston, Massachusetts $2.69B AUM 15.82% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Formidable Asset Management Cincinnati, Ohio $680M AUM 8.59% 1-Year Est. Return

180 Wealth Advisors Federal Way, Washington $1.04B AUM 41.44% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return

Advisors Asset Management Monument, Colorado $6.34B AUM 22.84% 1-Year Est. Return

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $840M AUM 13.7% 1-Year Est. Return

Z3 Capital Partners's HQL Position: Q3 2026 in Review

Z3 Capital Partners increased its abrdn Life Sciences Investors (HQL) stake by 6.2% in Q3 2026, buying an estimated $91K and bringing the position to 76,530 shares worth $1.43M. The position accounts for 0.3% of the portfolio, ranked #65.

Z3 Capital Partners first reported a position in HQL in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.44M in Q2 2026. 73 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

Z3 Capital Partners held 76,530 shares of abrdn Life Sciences Investors worth $1.43M as of Q3 2026.
Z3 Capital Partners bought 4,500 abrdn Life Sciences Investors shares in Q3 2026, an estimated $91K.
abrdn Life Sciences Investors made up 0.3% of Z3 Capital Partners's portfolio in Q3 2026, its #65 holding.
Z3 Capital Partners first reported a position in abrdn Life Sciences Investors in Q4 2025 and has held it in 4 quarters since.
Z3 Capital Partners's abrdn Life Sciences Investors position peaked at $1.44M in Q2 2026.
73 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on Z3 Capital Partners's 13F filing for Q3 2026, filed 10 Nov 2026.